Spots Global Cancer Trial Database for myelodysplastic syndromes (mds)
Every month we try and update this database with for myelodysplastic syndromes (mds) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS) | NCT03057990 | Myelodysplastic... | Pyrimethamine | 18 Years - | Montefiore Medical Center | |
| A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) | NCT02158936 | Thrombocytopaen... | Eltrombopag Azacitidine Placebo Placebo | 18 Years - | Novartis | |
| Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia | NCT00528983 | Myelodysplastic... Chronic Myelomo... Acute Myelogeno... | Subcutaneous (S... Oral Azacitidin... Oral Azacitidin... | 18 Years - | Celgene | |
| A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes | NCT00600860 | Myelodysplastic... | No intervention... | 18 Years - | Radboud University Medical Center | |
| LBH589 in Refractory Myelodysplastic Syndromes (MDS) | NCT00594230 | Myelodysplastic... | Panobinostat | 18 Years - | SCRI Development Innovations, LLC | |
| Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies | NCT00186342 | Acute Disease Myelodysplastic... Leukemia, Myelo... Myeloproliferat... Blood and Marro... Myelodysplastic... Leukemia | ablative alloge... | 51 Years - 60 Years | Stanford University | |
| Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence | NCT04797000 | Myelodysplastic... | Eltrombopag Placebo | 20 Years - 99 Years | Novartis | |
| A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes | NCT04985656 | Myelodysplastic... | Pevonedistat Decitabine Cedazuridine | 18 Years - | Takeda | |
| Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) | NCT04395092 | Acute Myeloid L... Myelodysplastic... | K-NK002 Conditioning Re... HaploBMT | 18 Years - 65 Years | Kiadis Pharma | |
| Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies | NCT00186342 | Acute Disease Myelodysplastic... Leukemia, Myelo... Myeloproliferat... Blood and Marro... Myelodysplastic... Leukemia | ablative alloge... | 51 Years - 60 Years | Stanford University | |
| Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell | NCT01660607 | Myeloid Leukemi... Acute Myelogeno... Myelodysplastic... Lymphoma, Non-H... Acute Lymphobla... Myeloproliferat... Acute Myeloid L... Acute Leukemia Chronic Myeloge... | Conventional T ... | 13 Years - 60 Years | Stanford University | |
| A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia | NCT01488565 | Myelodysplastic... Acute Myeloid L... | Azacitidine and... | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | NCT04064060 | Myelodysplastic... Beta-thalassemi... Myeloproliferat... | Luspatercept | 18 Years - | Celgene | |
| Pharmacokinetics, Tolerability and Safety of NEX-18a | NCT05048498 | Myelodysplastic... Chronic Myelomo... Acute Myeloid L... | NEX-18a injecti... Azacitidine Inj... | 18 Years - | Nanexa AB | |
| Panobinostat Maintenance After HSCT fo High-risk AML and MDS | NCT04326764 | Acute Myeloid L... Myelodysplastic... | Panobinostat | 18 Years - 70 Years | Goethe University | |
| A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS) | NCT00230321 | Blood Cancer Myelodysplastic... Myelodysplastic... | Darbepoetin alf... | 18 Years - | Stanford University | |
| A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS) | NCT02779569 | Myelodysplastic... | decitabine | 18 Years - 80 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) | NCT01736683 | Anemia Myelodysplastic... Chronic Myelomo... Low to Intermed... Myelodysplastic... Chronic Myelomo... | Sotatercept | 18 Years - | Merck Sharp & Dohme LLC | |
| Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders | NCT01392989 | Neural Tube Def... Anemia Leukemia, Myelo... Bone Marrow Tra... Myelodysplastic... Myeloproliferat... | CIK cells Cyclosporine Mycophenolate M... Thymoglobulin Total Lymphoid ... | 50 Years - | Stanford University | |
| Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia | NCT01034592 | Anemia Leukemia Acute Myeloid L... Myelodysplastic... | Lenalidomide | 18 Years - | Stanford University | |
| Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS) | NCT03057990 | Myelodysplastic... | Pyrimethamine | 18 Years - | Montefiore Medical Center | |
| A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients | NCT01613976 | Myelodysplastic... Chronic Myelomo... Acute Myeloid L... | Panobinostat | 20 Years - | Novartis | |
| Red Blood Cell Transfusion Thresholds and QOL in MDS | NCT02099669 | Myelodysplastic... Quality of Life Red Blood Cell ... | Red Blood Cell ... | 18 Years - | Sunnybrook Health Sciences Centre | |
| A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. | NCT04275518 | Acute Myeloid L... Myelodysplastic... | APG-115 Azacitidine Cytarabine | 18 Years - | Ascentage Pharma Group Inc. | |
| IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | NCT01885897 | Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Lymphoma Myeloma Chronic Lymphoc... Chronic Myeloge... | ALT-803 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Cord Blood Transplant in Adults With Blood Cancers | NCT05884333 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... Myeloproliferat... Non-Hodgkin's L... | Conditioning Ch... Cord blood graf... | 21 Years - 65 Years | Memorial Sloan Kettering Cancer Center | |
| Screening and Genetic Monitoring of Patients With Myelodysplastic Syndromes (MDS) Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+Cells | NCT01355913 | Myelodysplastic... Chromosmal Aber... Karyotype Evolu... Rare Abnormalit... Cytogenetic Mon... | 18 Years - | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH | ||
| LBH589 in Refractory Myelodysplastic Syndromes (MDS) | NCT00594230 | Myelodysplastic... | Panobinostat | 18 Years - | SCRI Development Innovations, LLC | |
| Cord Blood Transplant in Adults With Blood Cancers | NCT05884333 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... Myeloproliferat... Non-Hodgkin's L... | Conditioning Ch... Cord blood graf... | 21 Years - 65 Years | Memorial Sloan Kettering Cancer Center | |
| Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS) | NCT01822691 | Myelodysplastic... | INCB024360 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | NCT03214666 | High-risk Myelo... Acute Myelogeno... Systemic Mastoc... Mast Cell Leuke... | GTB-3550 TriKE®... GTB-3550 TriKE®... | 18 Years - | GT Biopharma, Inc. | |
| A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) | NCT02158936 | Thrombocytopaen... | Eltrombopag Azacitidine Placebo Placebo | 18 Years - | Novartis | |
| Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse | NCT01995578 | Myelodysplastic... Acute Myelogeno... | low dose 5'-aza... | 1 Year - 75 Years | Memorial Sloan Kettering Cancer Center | |
| Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood | NCT00662090 | Myelodysplastic... Juvenile Myelom... | - 215 Months | University Hospital Freiburg | ||
| Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies | NCT02333058 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... Juvenile Myelom... | Treosulfan | 28 Days - 17 Years | medac GmbH | |
| Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes | NCT04997811 | Myelodysplastic... | Sodium Valproat... Danazol | 18 Years - | University of Warwick | |
| A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia). | NCT05927012 | Iron Deficiency... | KER-047 | 18 Years - | Keros Therapeutics, Inc. | |
| Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies | NCT02333058 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... Juvenile Myelom... | Treosulfan | 28 Days - 17 Years | medac GmbH | |
| Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders | NCT00186576 | Myelodysplastic... Myeloproliferat... Blood and Marro... Myelodysplastic... Myeloproliferat... | nonmyeloablativ... | 18 Years - 75 Years | Stanford University | |
| B-Receptor Signaling in Cardiomyopathy | NCT01135849 | Carcinomas Amyloidosis Anal Cancer Anemia Cholangiocarcin... Transitional Ce... Bone Marrow Tra... Bone Cancer Cancer of Brain... Breast Cancer Carcinoma of th... Endocrine Cance... Esophageal Canc... Eye Cancer Gall Bladder Ca... Gastric (Stomac... Gastrooesophage... Gastrointestina... Gynecologic Can... Head and Neck C... Hepatobiliary N... Kidney (Renal C... Leukemia Lung Cancer Hodgkin Disease Lymphoma, Non-H... Mesothelioma Multiple Myelom... Myelodysplastic... Neuroendocrine ... Myeloproliferat... Pancreatic Canc... Prostate Cancer Skin Cancer Soft Tissue Sar... Testicular Canc... Thymus Cancer Thyroid Cancer | - 40 Years | Stanford University | ||
| Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) | NCT04395092 | Acute Myeloid L... Myelodysplastic... | K-NK002 Conditioning Re... HaploBMT | 18 Years - 65 Years | Kiadis Pharma | |
| LBH589 in Refractory Myelodysplastic Syndromes (MDS) | NCT00594230 | Myelodysplastic... | Panobinostat | 18 Years - | SCRI Development Innovations, LLC | |
| Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders | NCT01392989 | Neural Tube Def... Anemia Leukemia, Myelo... Bone Marrow Tra... Myelodysplastic... Myeloproliferat... | CIK cells Cyclosporine Mycophenolate M... Thymoglobulin Total Lymphoid ... | 50 Years - | Stanford University | |
| B-Receptor Signaling in Cardiomyopathy | NCT01135849 | Carcinomas Amyloidosis Anal Cancer Anemia Cholangiocarcin... Transitional Ce... Bone Marrow Tra... Bone Cancer Cancer of Brain... Breast Cancer Carcinoma of th... Endocrine Cance... Esophageal Canc... Eye Cancer Gall Bladder Ca... Gastric (Stomac... Gastrooesophage... Gastrointestina... Gynecologic Can... Head and Neck C... Hepatobiliary N... Kidney (Renal C... Leukemia Lung Cancer Hodgkin Disease Lymphoma, Non-H... Mesothelioma Multiple Myelom... Myelodysplastic... Neuroendocrine ... Myeloproliferat... Pancreatic Canc... Prostate Cancer Skin Cancer Soft Tissue Sar... Testicular Canc... Thymus Cancer Thyroid Cancer | - 40 Years | Stanford University | ||
| Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies | NCT06398457 | Hematologic Mal... Bone Marrow Tra... Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Multiple Myelom... Aplastic Anemia Lymphoma Non Hodgkin Lym... Hodgkin Lymphom... Chronic Myeloid... Myelofibrosis | Darzalex Faspro... JH-DSA Semi-Qua... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
